Search results
May 9, 2024 · Paxlovid rebound typically happens within a week after you've taken Paxlovid to treat COVID-19. With Paxlovid rebound, either your COVID-19 symptoms return or you test positive after testing negative.
Apr 15, 2024 · Paxlovid rebound, also known as COVID rebound, is a recurrence of COVID symptoms or a positive test result taken after having the disease and testing negative. Yale experts tell you what you need to know.
Aug 8, 2022 · The CDC defines Paxlovid rebound as when a patient who, after receiving a full five-day course of treatment, either has a reemergence of COVID symptoms or tests positive after a previous,...
Feb 20, 2024 · What initially was referred to as “Paxlovid rebound”—a return of COVID symptoms or test positivity after starting a course of the antiviral—is now more accurately referred to as “COVID rebound,” because rebound can happen regardless of whether someone takes antivirals.
1 day ago · There have been reports of a “rebound” of COVID symptoms in some people within 2 to 8 days after completing the five-day course of Paxlovid; in those cases, some have tested positive again but have no symptoms; others have a recurrence of symptoms.
Sep 26, 2023 · The theory behind Paxlovid rebound is that the treatment is so effective at suppressing the virus that the immune system does not ramp up its cellular and antibody...
Dec 13, 2022 · Those who have taken Paxlovid and are concerned about a potential rebound should watch out for returning symptoms in the week or so after they test negative.
May 31, 2022 · Here’s what we know about Paxlovid rebound so far. Why do people even take Paxlovid if their COVID-19 could rebound?
Jun 21, 2022 · The authors said the rebound of COVID-19 symptoms following the end of Paxlovid treatment is likely due to insufficient drug exposure: not enough of the drug was getting to infected cells to stop all viral replication.
Currently, there are no reports of severe disease among persons with COVID-19 rebound. Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease.
